GlycoMimetics (GLYC) Reports Q3 Loss of $0.29/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to GlycoMimetics (GLYC) Reports Q3 Loss of $0.29/sh

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020

November 6, 2020 7:30 AM EST

Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continues on track, and the Company reiterates its prior guidance that completion of enrollment for the Company-sponsored Phase 3 trial is expected in the second half of 2021 Enrollment also continues in the National Cancer Institute (NCI)-sponsored Phase 3 trial to evaluate uproleselan for newly-diagnosed AML patients fit for chemotherapy Three oral presentations and two additional poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting will highlight the GlycoMimetics pipeline; multiple... More